Marinus Pharma Shares Up After Deal for Rare Pediatric Disease Priority Review Voucher

Marinus Pharmaceuticals Inc. shares were higher premarket Thursday after the pharmaceutical company agreed to sell its Rare Pediatric Disease Priority Review Voucher for $110 million, a move the company said will strengthen its financial position.